bioAffinity Technologies, Inc. (BIAF)
2.15
+0.22
(+11.40%)
USD |
NASDAQ |
Nov 18, 16:00
2.08
-0.07
(-3.26%)
After-Hours: 20:00
bioAffinity Technologies Enterprise Value : 1.456M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 1.456M |
| November 17, 2026 | 1.200M |
| November 16, 2026 | 1.281M |
| November 13, 2026 | 1.514M |
| November 12, 2026 | 1.678M |
| November 11, 2026 | 1.777M |
| November 10, 2026 | 1.736M |
| November 09, 2026 | 1.584M |
| November 06, 2026 | 2.115M |
| November 05, 2026 | 1.981M |
| November 04, 2026 | 2.366M |
| November 03, 2026 | 2.670M |
| November 02, 2026 | 2.436M |
| October 30, 2026 | 2.343M |
| October 29, 2026 | 2.483M |
| October 28, 2026 | 2.611M |
| October 27, 2026 | 2.401M |
| October 26, 2026 | 2.250M |
| October 23, 2026 | 2.214M |
| October 22, 2026 | 2.646M |
| October 21, 2026 | 3.113M |
| October 20, 2026 | 3.218M |
| October 19, 2026 | 3.043M |
| October 16, 2026 | 3.299M |
| October 15, 2026 | 3.568M |
| Date | Value |
|---|---|
| October 14, 2026 | 3.101M |
| October 13, 2026 | 3.177M |
| October 12, 2026 | 3.498M |
| October 09, 2026 | 4.460M |
| October 08, 2026 | 5.528M |
| October 07, 2026 | 6.134M |
| October 06, 2026 | 6.018M |
| October 05, 2026 | 6.169M |
| October 02, 2026 | 6.012M |
| October 01, 2026 | 6.117M |
| September 30, 2026 | 6.601M |
| September 29, 2026 | 2.116M |
| September 28, 2026 | 2.356M |
| September 25, 2026 | 2.591M |
| September 24, 2026 | 2.546M |
| September 23, 2026 | 2.596M |
| September 22, 2026 | 2.874M |
| September 21, 2026 | 2.487M |
| September 18, 2026 | 3.270M |
| September 17, 2026 | 2.962M |
| September 16, 2026 | 1.425M |
| September 15, 2026 | 1.881M |
| September 14, 2026 | 2.591M |
| September 11, 2026 | 2.600M |
| September 10, 2026 | 3.252M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 163.62M |
| Perspective Therapeutics, Inc. | -108.96M |
| MiMedx Group, Inc. | 343.25M |
| Veracyte, Inc. | 1.733B |
| T2 Biosystems, Inc. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.277M |
| Revenue (Quarterly) | 1.070M |
| Total Expenses (Quarterly) | 6.347M |
| EPS Diluted (Quarterly) | -5.888 |
| Gross Profit Margin (Quarterly) | -10.34% |
| Profit Margin (Quarterly) | -493.0% |
| Earnings Yield | -1.77K% |
| Normalized Earnings Yield | -1709.68 |